The review of the questionnaire about the effectiveness of Sumatriptane (CROSBI ID 546337)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Strahinja, Višnja ; Willheim, Ksenija ; Šepić Grahovac, Dubravka
engleski
The review of the questionnaire about the effectiveness of Sumatriptane
We wanted to evaluate the effectiveness of sumatriptane by analysing the questionnaire filled by patients suffering from migraine. The questionnaire consisted of four questions: which dosage of sumatriptane do you use in migraine attacks? How would you evaluate the effectiveness of this dosage of sumatriptane? Account all other drugs you used before in treating migraine attacks? How would you evaluate the effectiveness of those drugs in comparison to sumatriptane? We analysed 97 questionnaires and found: 47% of patients used 50 mg sumatriptane, 43% used 100 mg, and 10% used 200 mg sumatriptane. The dosage is excellent in 68%, good in 28% and inefficient in 10 patients. Before sumatriptane 64% used dihydroergotamine, 28% caffetine, 10% Aspirine and 10% noraminophenasone. 89% said sumatriptane is more efficient, 4% thought that the efficiency is the same, and 7% evaluated lesser effectiveness.The questionnaire showed that 50, 100 mg of sumatriptane is enough for a desired effect, 90% of patients evaluated excellent or good efficiency of sumatriptane, 89% as a far more efficient. We should have more analogue questionnaires for drugs which are on the market more than five years to get better feedback.
Migraine; Sumatriptane
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
100-x.
2000.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Abstracts
Beč: International Pharmaceutical Federation (FIP)
Podaci o skupu
Pharmacy World Congress 2000
poster
26.08.2000-31.08.2000
Beč, Austrija